Literature DB >> 15292337

Morning preprandial plasma ghrelin and catecholamine concentrations in patients with phenylketonuria and normal controls: evidence for catecholamine-mediated ghrelin regulation.

Kleopatra H Schulpis1, Ioannis Papassotiriou, Maria Vounatsou, George A Karikas, Stylianos Tsakiris, George P Chrousos.   

Abstract

Patients with phenylketonuria (PKU) have a diet-controlled deficiency in the conversion of phenylalanine (Phe) to tyrosine (Tyr), leading to decreased production of noradrenaline, adrenaline, and dopamine. Poor diet control results in high plasma Phe and low plasma Tyr and catecholamine concentrations. Ghrelin, a recently described gastrointestinal hormone that is elevated in the fasting state and low in the fed state, is considered a major appetite-stimulating hormone, possibly involved in the generation of obesity and insulin resistance. We evaluated morning preprandial plasma ghrelin levels in 14 diet-controlled and 15 poorly controlled PKU patients and 20 age- and body mass index (BMI)-matched healthy children (controls) and correlated its concentrations with those of Phe and catecholamines as well as with their BMI and 24-h nutrient intake. Plasma ghrelin levels were measured by RIA, plasma catecholamine concentrations were determined by HPLC with electrochemical detection, and Phe and Tyr levels were measured in an amino acid analyzer. The ghrelin concentration (744 +/- 25 ng/liter) in diet-controlled patients did not differ from that in controls (802 +/- 26 ng/liter; P > 0.05). On the contrary, the ghrelin concentration was significantly reduced in poorly controlled patients (353 +/- 23 ng/liter; P < 0.0001). Ghrelin correlated negatively with Phe in all three groups, whereas it correlated positively with catecholamine levels and energy intake and negatively with BMI only in diet-controlled patients and controls. We conclude that ghrelin secretion may receive positive direct or indirect input from catecholamines. The absence of a correlation between ghrelin and catecholamines, energy intake, or BMI in PKU patients on an inadequate diet may be due to dysregulation of their neuroendocrine system and might be affected by high Phe levels in the stomach and/or central nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292337     DOI: 10.1210/jc.2004-0311

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  Regular exercise prevents oxidative stress in the brain of hyperphenylalaninemic rats.

Authors:  Priscila Nicolao Mazzola; Melaine Terra; Andrea Pereira Rosa; Caroline Paula Mescka; Tarsila Barros Moraes; Bruna Piccoli; Carlos Eduardo Jacques; Giovana Dalazen; Marcelo Xavier Cortes; Juliana Coelho; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2011-09-27       Impact factor: 3.584

3.  Peptide tyrosine tyrosine levels are increased in patients with urea cycle disorders.

Authors:  Sabrina Mitchell; Teresa Welch-Burke; Logan Dumitrescu; Jefferson P Lomenick; Deborah G Murdock; Dana C Crawford; Marshall Summar
Journal:  Mol Genet Metab       Date:  2012-02-22       Impact factor: 4.797

4.  Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria.

Authors:  Erin L MacLeod; Murray K Clayton; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2010-04-14       Impact factor: 4.797

5.  Co-administration of creatine plus pyruvate prevents the effects of phenylalanine administration to female rats during pregnancy and lactation on enzymes activity of energy metabolism in cerebral cortex and hippocampus of the offspring.

Authors:  Vanessa Trindade Bortoluzzi; Itiane Diehl de Franceschi; Elenara Rieger; Clóvis Milton Duval Wannmacher
Journal:  Neurochem Res       Date:  2014-06-11       Impact factor: 3.996

6.  COMPARISON OF PLASMA PHENYLALANINE DETERMINATION BY DENSITOMETRY OF THIN-LAYER CHROMATOGRAMS AND BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY IN RELATION WITH THE SCREENING OF PHENYLKETONURIA.

Authors:  C V Mihali; M C Petrescu; I Mândruţiu; D Bechet; T V Nistor; V Turcuş; A Ardelean; Gh Benga
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Apr-Jun       Impact factor: 0.877

7.  Analysis of body composition and nutritional status in Brazilian phenylketonuria patients.

Authors:  Priscila Nicolao Mazzola; Tatiele Nalin; Kamila Castro; Margreet van Rijn; Terry G J Derks; Ingrid D S Perry; Alberto Scofano Mainieri; Ida Vanessa D Schwartz
Journal:  Mol Genet Metab Rep       Date:  2016-01-09

8.  Metabolic and catecholamine response to sympathetic stimulation in early-treated adult male patients with phenylketonuria.

Authors:  Csaba Sumanszki; Krisztian Kovacs; Gellert Balazs Karvaly; Erika Kiss; Erika Simon; Attila Patocs; Miklos Toth; Zsolt Komka; Peter Reismann
Journal:  Hormones (Athens)       Date:  2020-01-28       Impact factor: 2.885

Review 9.  The role of "mixed" orexigenic and anorexigenic signals and autoantibodies reacting with appetite-regulating neuropeptides and peptides of the adipose tissue-gut-brain axis: relevance to food intake and nutritional status in patients with anorexia nervosa and bulimia nervosa.

Authors:  Kvido Smitka; Hana Papezova; Karel Vondra; Martin Hill; Vojtech Hainer; Jara Nedvidkova
Journal:  Int J Endocrinol       Date:  2013-09-09       Impact factor: 3.257

10.  Comparison of Glycomacropeptide with Phenylalanine Free-Synthetic Amino Acids in Test Meals to PKU Patients: No Significant Differences in Biomarkers, Including Plasma Phe Levels.

Authors:  Kirsten K Ahring; Allan M Lund; Erik Jensen; Thomas G Jensen; Karen Brøndum-Nielsen; Michael Pedersen; Allan Bardow; Jens Juul Holst; Jens F Rehfeld; Lisbeth B Møller
Journal:  J Nutr Metab       Date:  2018-01-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.